6127ac90aa40346ca9889744 evaluation-of-pharmacologic-treatments-for-h1-antihistamine-refractory-chronic-spontaneous-urticaria-a-systematic-review-and-network-meta-analysis 2021-08-26T18:10:52.244Z 5e283dc83b5e750642253bd0 3665f6cd-25c6-4c1b-9a81-3f61a93a68e4 mas_evidence_types:Systematic%20reviews Systematic reviews and meta-analyses Network meta-analysis (23 RCTs; n=2480) found the biologic agents ligelizumab, (72 or 240 mg; large beneficial effect) and omalizumab (300 or 600 mg; moderate beneficial effect), appeared to be effective treatments for H1 antihistamine–refractory chronic spontaneous urticaria. <p>The standardized mean differences for change in urticaria symptoms compared to placebo were &minus;1.05 (95% CI, &minus;1.37 to &minus;0.73) for ligelizumab, 72 mg; &minus;1.07 (95% CI, &minus;1.39 to &minus;0.75) for ligelizumab, 240 mg; &minus;0.77 (95% CI, &minus;0.91 to &minus;0.63) for omalizumab, 300 mg; and &minus;0.59 (95% CI, &minus;1.10 to &minus;0.08) for omalizumab, 600 mg.</p> <p>Ligelizumab, humanised anti-IgE monoclonal antibody that belongs to the IgG1/&kappa; isotype subclass, is currently in phase III clinical trials and was granted breakthrough therapy designation in US in Jan 2021.</p> https://www.medicinesresources.nhs.uk/evaluation-of-pharmacologic-treatments-for-h1-antihistamine-refractory-chronic-spontaneous-urticaria-a-systematic-review-and-network-meta-analysis.html https://jamanetwork.com/journals/jamadermatology/article-abstract/2783033 2021-04-25T00:00:00Z 2021-08-26T15:00:32.229Z